Literature DB >> 20674536

Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study.

W Thomas Johnston1, Tracy J Lightfoot, Jill Simpson, Eve Roman.   

Abstract

BACKGROUND: Improvements in diagnostic approaches and refinements to treatment protocols have resulted in 5-year survival levels above 70% for children diagnosed with cancer in economically developed parts of the world. For some cancers, including leukaemia and tumours of the central nervous system, age and sex have been identified as important prognostic indicators.
METHODS: We examined long-term survival, and affects of age and sex, in a population-based case-control study. Children (0-14 years) newly diagnosed with cancer were ascertained between 1991 and 1996 (n=4433). Follow-up information was obtained from the National Health Service (NHS) Information Centre for Health and Social Care which records all exits from the NHS including deaths.
RESULTS: For all cancer diagnoses combined, 5-year survival was 72.7% dropping to 67.9% at 15 years. As expected, survival differed between diagnostic subtypes ranging from 38.1% for intracranial embryonal tumours to 96.2% for Hodgkin lymphoma. Compared to girls, boys diagnosed with acute lymphoblastic leukaemia were at a higher risk of dying (RR=1.26, 95% CI 1.03-1.53), whereas boys diagnosed with an intracranial embryonal tumour were at a lower risk of death (RR=0.63, 95% CI 0.43-0.91).
CONCLUSION: Our initial findings are consistent with previous reports, and highlight the importance of considering differences by age and sex. The completeness and population-based nature of the original case-control study is an important feature which will provide the basis for future more detailed investigations linking disease determinants to outcome.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20674536     DOI: 10.1016/j.canep.2010.06.020

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  9 in total

1.  ABCB1 polymorphism and susceptibility to acute lymphoblastic leukemia: a meta analysis.

Authors:  Haiyan Zhang; Zhen Zhang; Guang Li
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility.

Authors:  Ángela Gutiérrez-Camino; Elixabet López-López; Idoia Martín-Guerrero; José Sánchez-Toledo; Nagore García de Andoin; Ana Carboné Bañeres; Purificación García-Miguel; Aurora Navajas; África García-Orad
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-08       Impact factor: 4.553

3.  Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis.

Authors:  C Zhu; Y W Liu; S Z Wang; X L Li; X L Nie; X T Yu; L B Zhao; X L Wang
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

4.  Childhood Cancer Survival, 2006-2012 Cohorts of Mexican Institute of Social Security Beneficiaries at the Central-South Region of Mexico.

Authors:  Angélica Castro-Ríos; Silvia Martínez-Valverde
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

5.  Survival from childhood cancer in northern England, 1968-2005.

Authors:  N O Basta; P W James; B Gomez-Pozo; A W Craft; R J Q McNally
Journal:  Br J Cancer       Date:  2011-09-20       Impact factor: 7.640

6.  Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.

Authors:  Elixabet López-López; Ángela Gutiérrez-Camino; Maria Ángeles Piñán; José Sánchez-Toledo; Jose Javier Uriz; Javier Ballesteros; Purificación García-Miguel; Aurora Navajas; África García-Orad
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

7.  Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies.

Authors:  Hiroko Fukushima; Takashi Fukushima; Aiko Sakai; Ryoko Suzuki; Ryoko Nakajima-Yamaguchi; Chie Kobayashi; Atsushi Iwabuchi; Makoto Saito; Ai Yoshimi; Tomohei Nakao; Keisuke Kato; Masahiro Tsuchida; Hideto Takahashi; Kazutoshi Koike; Nobutaka Kiyokawa; Emiko Noguchi; Ryo Sumazaki
Journal:  Leuk Res Treatment       Date:  2013-12-10

Review 8.  MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.

Authors:  Maitane Umerez; Ángela Gutierrez-Camino; Carmen Muñoz-Maldonado; Idoia Martin-Guerrero; Africa Garcia-Orad
Journal:  Pharmgenomics Pers Med       Date:  2017-03-27

9.  Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort.

Authors:  Eleanor Kane; Sally Kinsey; Audrey Bonaventure; Tom Johnston; Jill Simpson; Debra Howell; Alexandra Smith; Eve Roman
Journal:  BMJ Open       Date:  2022-03-07       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.